Healthcare stocks rise during market volatility

The healthcare sector has been on fire over the last several years, with investors in the space seeing big returns on stocks. Even during periods of volatility across the stock market at the end of 2018, the healthcare sector remained consistent, with “stellar returns,” Bloomberg reported.

The end of 2018 was one of only four periods when valuations swung up and down so intensely. However, the 60 publicly traded companies in the S&P 500’s Health Care Index did just fine. In fact, they were the “sole mainstay” as market winners amid all those swing periods, according to Bloomberg.

While the S&P 500, Dow Jones Industrial Average and Nasdaq faltered as much as 5 percent at the end of 2018, three of the top five U.S.-based mutual funds with assets greater than $5 billion specialized in healthcare stocks.

Unlike other sectors, the healthcare space isn’t as impacted by global economic volatility.

“Rising demand for health-related products and services, regardless of the economy’s cycle, military conflicts and political firestorms, helps explain why health-care investors can ignore Trump’s daily tweets and his tariffs on trade with Canada, China, Mexico and the EU,” Bloomberg reported.

The sector has been performing well since the Affordable Care Act, in particular.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.